◈ Nootpedia
Compact view
Research pass: medium Pharmaceutical · Oral SKIP-PERMANENT HIGH

Adrafinil

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-PERMANENT HIGH

Modafinil is now $0.50-1.50/pill via Indian pharmacy and bypasses the hepatic prodrug step entirely. Adrafinil is strictly worse on every metric (slower onset, 3-4× higher mg, hepatotoxicity signal that withdrew it from the French market in 2011) with no compensating benefit. Verdict would only change if modafinil sourcing globally collapsed AND adrafinil access remained — currently inverted.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-PERMANENT

    Modafinil 100 mg AM via Indian pharmacy is strictly dominant — same downstream pharmacology, faster onset, no hepatic prodrug toll, no LFT monitoring burden, cheaper, more reliable supply. Zero rational reason to choose adrafinil.

  • 30-50, executive maintenance
    SKIP-PERMANENT

    Same logic. Even cleaner Rx access via US telehealth.

  • 50+, mild cognitive decline
    SKIP-PERMANENT

    Higher baseline hepatic vulnerability + medication burden = adrafinil's hepatotoxicity is a bigger problem here, not smaller. Modafinil with LFT monitoring still preferable; donepezil/rivastigmine for disease-specific use cases.

  • Anxiety-prone
    SKIP-PERMANENT

    Adrafinil reportedly produces more anxiety than modafinil per French surveillance. No rationale.

  • High athletic load, tested status
    SKIP-PERMANENT

    WADA bans modafinil S6 in-competition; adrafinil converts to modafinil so it's the same ban with extra steps. Tested athletes have no use case.

  • Sleep-disordered
    SKIP-PERMANENT

    Modafinil/armodafinil/solriamfetol/pitolisant are FDA-approved with cleaner safety profiles. Adrafinil is obsolete here.

  • Recovery-focused (post-injury, post-illness)
    SKIP-PERMANENT

    Adding hepatic load to a body in recovery is the wrong direction.

  • Strength/anabolic-focused
    SKIP-PERMANENT

    No anabolic effect. Hepatotoxicity stacks badly with oral AAS use, methylated supplements, kava, alcohol, etc. Universal verdict: Adrafinil is dominated by modafinil for every user archetype. There is no preference profile under which adrafinil wins.

▸ Subjective experience (deep)

Onset: ~45-60 minutes orally on empty stomach (vs modafinil's 30-90 min). The conversion delay is the only real subjective difference.

Peak: 2-3 hours post-dose (1-2 hours later than modafinil itself).

Plateau: Once plasma modafinil reaches steady state, the experience is modafinil's experience — alert, focused, motivated, no euphoria, low peripheral sympathetic load.

Taper: Same as modafinil (driven by R-modafinil's 12-15 hour half-life).

Characteristic effects (above and beyond modafinil):

  • More frequent stomach upset / GI complaints (likely from the unreduced sulfoxide intermediate or hydroxylamide moiety)
  • Higher reported skin irritation
  • More commonly reported anxiety and elevated liver enzyme symptoms (RUQ discomfort, fatigue) at chronic dose

Honest variability: Because the conversion enzyme load is variable (CYP3A4/3A5, hepatic sulfoxide reductase capacity), interindividual variance in adrafinil response is higher than modafinil — some users get strong modafinil effects from 300 mg adrafinil, others need 1200 mg.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Same as modafinil — minimal pharmacodynamic tolerance. The cycling discussion is dominated by hepatotoxicity, not receptor desensitization.
  • Recommended cycle: Don't. If a user insists, 4-5 days/week with 2-week breaks every 2-3 months and quarterly LFT monitoring is the absolute minimum. But the better protocol is "don't take adrafinil — take modafinil."
  • Reset protocol: If LFTs elevated on chronic adrafinil, full discontinuation with LFT recheck at 6-8 weeks off-drug. Most cases normalize.
▸ Stacking deep dive

Synergistic with

  • N/A — once converted to modafinil, the synergy profile is modafinil's (l-theanine, citicoline, rhodiola, bromantane, selegiline). But there is no reason to stack onto adrafinil specifically when the modafinil-on-board version of the same stack is cleaner.

Avoid stacking with

  • Other hepatotoxic compounds — alcohol (any amount), high-dose acetaminophen, statins, methotrexate, isoniazid, kava, comfrey, high-dose niacin. The additive hepatic load is the major issue.
  • CYP3A4 inhibitors that would slow conversion — paradoxically would reduce adrafinil → modafinil conversion AND extend exposure to the unconverted parent compound. Worst of both worlds.
  • Hormonal contraceptives — same CYP3A4 induction issue as modafinil; reduced contraceptive efficacy during use and 1 month after.

Neutral / safe co-administration

  • All Dylan's V4 supplements would be neutral pharmacologically but adrafinil's hepatic load makes co-administration of NAC essentially mandatory as a hedge — and at that point you're just patching a wound that modafinil wouldn't have created.
▸ Drug interactions deep dive

Once converted to modafinil, the interaction profile is identical to modafinil:

  • Hormonal contraceptive efficacy reduced (CYP3A4 induction) during use and 1 month after
  • Opioid analgesia possibly reduced (CYP3A4 induction)
  • CYP2C19 substrates possibly increased (mild inhibition)
  • CYP3A4 substrates possibly reduced (induction)

Adrafinil-specific additional concerns:

  • Compounds that induce or inhibit hepatic sulfoxide reduction may unpredictably alter conversion efficiency.
  • Co-administered hepatotoxins (alcohol, acetaminophen, high-dose statins) compound the LFT-elevation risk.
▸ Pharmacogenomics
  • CYP3A4/3A5 polymorphism — CYP3A5 expressers (~10% of Caucasians) may convert adrafinil faster, with higher peak plasma modafinil. Effect is modest.
  • CYP2C19 polymorphism — affects modafinil S-enantiomer clearance once formed. PMs see ~20-30% higher modafinil exposure for any given conversion yield.
  • Hepatic capacity polymorphisms — individuals with subclinical hepatic insufficiency (NAFLD, hepatitis history, heavy alcohol exposure, certain HLA-B alleles) may face dramatically elevated hepatotoxicity risk on adrafinil specifically. Modafinil bypasses this concern.
  • For Dylan: No bloodwork yet (June 2026 baseline pending). Even with normal LFTs, there is no reason to take a hepatotoxic prodrug when the active metabolite is independently available.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem vendor Various US/EU online $30-60/month at 600 mg/day Low-medium — FDA issued warning letters 2019; $2.4M FDA fine to Arizona vendor 2023 Post-Olmifon withdrawal (2011), no pharmaceutical-grade source remains. All current supply is research-chem with variable purity.
Gray-market nootropic vendor NootropicsDepot, Liftmode (historical) Similar Variable Most US vendors have stopped stocking after FDA enforcement. Active 2025-2026 supply is consolidated and unreliable.
Indian online pharmacy None confirmed for adrafinil N/A N/A Indian generic infrastructure is built around modafinil/armodafinil, not adrafinil. No reason for an Indian pharmacy to stock the prodrug.
Rx in any jurisdiction None N/A N/A Olmifon withdrawn worldwide 2011. No country currently approves adrafinil for clinical use.

Bottom line on sourcing: Adrafinil is a research-chem-only compound in 2026, with active FDA enforcement against US distributors. Modafinil sourcing (Indian pharmacy, US telehealth Rx) is dramatically cleaner.

▸ Biomarkers to track (deep)

If used despite the universal SKIP recommendation:

Baseline (before starting)

  • ALT, AST, GGT, alkaline phosphatase, total bilirubin, albumin (full LFT panel)
  • Hepatitis B/C serology
  • Resting HR + BP
  • Skin photographic baseline (week 1-8 SJS watch)

During use

  • Week 4: full LFT panel — stop drug if ALT or AST >3× ULN, or any clinical symptoms (RUQ pain, jaundice, dark urine, persistent fatigue)
  • Week 12: full LFT panel — same threshold
  • Quarterly thereafter: full LFT panel
  • Weeks 1-8: daily skin check (SJS watch, inherited from modafinil)

Post-cycle

  • LFT recheck 6-8 weeks after discontinuation — most elevations normalize
▸ Controversies / open debates Live debate

1. "Adrafinil is gentler / safer than modafinil"

  • Forum claim: Slow onset = smoother experience. Some 2010s nootropic communities preferred adrafinil for this reason.
  • Clinical reality: "Slower onset" is a pharmacokinetic curiosity, not a safety advantage. Once steady-state modafinil is reached, the drug is modafinil. The hepatotoxicity signal is a real, measurable, regulator-confirmed downside that modafinil itself does not share.

2. "Adrafinil's OTC status makes it the only legal option"

  • Historical truth (2010-2018): Yes — for US users without Rx access, adrafinil was the only realistic eugeroic.
  • Current reality (2026): Indian pharmacy modafinil sourcing has been routine and reliable for a decade. US telehealth (Hello Klarity, Premier Hormone, others) writes modafinil Rx via SWSD/narcolepsy diagnoses. The legal-access argument has collapsed.

3. "The Olmifon withdrawal was about commercial reasons, not safety"

  • Counter-argument floated in some nootropic circles: Servier/Cephalon withdrew Olmifon to protect Provigil's market.
  • Actual record: The 2011 withdrawal cited "unfavorable risk-benefit ratio" with a specific hepatotoxicity safety signal documented in French post-marketing surveillance. The commercial-protection theory is unsupported by the regulatory paper trail. Adrafinil remained off-formulary in every country after 2011 — if it were merely a commercial maneuver, generic versions would have appeared in non-Cephalon territories. They have not.

4. "Conversion ratios are favorable — less drug for same effect"

  • Forum claim: "300 mg adrafinil = 100 mg modafinil, so it's actually a smaller dose."
  • Clinical reality: Inverted. You're putting more mass through the liver to achieve the same plasma modafinil. The "smaller dose" framing is wrong because the relevant exposure metric is hepatic load, not pill mg.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-PERMANENT / HIGH CONFIDENCE / MEDIUM-priority research pass. Confirms 2026-05-05 encyclopedia entry: "Skip. Modafinil itself is now cheap enough that there's no reason to add the liver burden." Universal SKIP across all archetypes. No conditions under which verdict would flip — modafinil dominates on every metric.
▸ Open questions / gaps Open
  1. No pharmacogenomic data on individual hepatotoxicity susceptibility — would HLA-B alleles or specific CYP polymorphisms predict the chronic-dose hepatitis cases? Unknown, and unlikely to be studied given commercial obsolescence.
  2. No head-to-head adrafinil vs modafinil safety RCT — the hepatotoxicity signal comes from post-marketing surveillance, not a controlled comparison. Not a meaningful gap because (a) the regulator-confirmed signal exists, and (b) modafinil's strictly dominant profile makes the comparison moot.
  3. What would change the verdict? Nothing realistic. Modafinil sourcing would have to globally collapse (Indian pharmacy crackdown + US telehealth ban + EU/UK Rx tightening simultaneously) AND adrafinil access would have to remain. This is a tail-of-tail-of-tail scenario.
▸ Sources (full, with our context)
Back to compact view